Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminated
NCT03829501Phase 1, Phase 2Updated Apr 2, 2025
Sponsor: Kymab Limited
Squamous Cell Carcinoma of Head and Neck · Non-small Cell Lung Cancer · Hepatocellular Carcinoma · Esophageal Cancer
United States, Hungary, Italy, Poland, Taiwan +1 more
Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell DiseaseCompleted
NCT02193191Phase 1Updated Mar 30, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Sickle Cell Disease
United States
BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic DermatitisRecruiting
NCT03549416N/AUpdated Mar 28, 2025
Sponsor: UMC Utrecht
Atopic Dermatitis
Netherlands
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injectorCompleted
NCT05129241N/AUpdated Mar 24, 2025
Sponsor: Sanofi
Primary Hypercholesterolaemia and Mixed Dyslipidaemia · Atherosclerotic Cardiovascular Disease
Germany
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24Completed
NCT06059456N/AUpdated Mar 24, 2025
Sponsor: Sanofi
Influenza Immunization (Healthy Volunteers)
Finland, Germany
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)Terminated
NCT05237284Phase 2Updated Mar 21, 2025
Sponsor: Sanofi
Amyotrophic Lateral Sclerosis
United States, Belgium, Canada, China, France +8 more
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and OlderCompleted
NCT05650554Phase 1, Phase 2Updated Mar 19, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
United States, Australia, Puerto Rico
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and OlderCompleted
NCT05624606Phase 1, Phase 2Updated Mar 18, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
United States, Puerto Rico
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)Completed
NCT01186224NAUpdated Mar 17, 2025
Sponsor: University of Liverpool
Multiple Myeloma · Plasma Cell Dyscrasia · Lymphoma · Lymphoproliferative Disorders
United Kingdom
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and LebanonCompleted
NCT03869866Phase 3Updated Mar 17, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
Lebanon, Turkey (Türkiye)
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompleted
NCT03547271Phase 3Updated Mar 3, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Czechia, Finland, Italy, Poland, Romania +2 more
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompleted
NCT04080531Phase 4Updated Feb 28, 2025
Sponsor: Emory University
Plasma Cell Neoplasm
United States
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)Recruiting
NCT05001087N/AUpdated Feb 27, 2025
Sponsor: Fondazione EMN Italy Onlus
Multiple Myeloma
Italy
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderActive Not Recruiting
NCT02202772Phase 1, Phase 2Updated Feb 24, 2025
Sponsor: Guarionex J. Decastro
Urothelial Carcinoma of the Urinary Bladder
United States
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)Completed
NCT04270942Phase 2Updated Feb 12, 2025
Sponsor: Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
United States
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa TreatmenCompleted
NCT04676373Phase 4Updated Feb 10, 2025
Sponsor: Genzyme, a Sanofi Company
Pompe's Disease
China
Evaluation of SAR408701 in Patients With Advanced Solid TumorsTerminated
NCT02187848Phase 1Updated Feb 10, 2025
Sponsor: Sanofi
Neoplasm Malignant
United States, Canada, France, South Korea, Spain
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in ChinaCompleted
NCT05680298Phase 4Updated Feb 10, 2025
Sponsor: Sanofi
Atopic Dermatitis
China
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in FranceCompleted
NCT05359276N/AUpdated Feb 6, 2025
Sponsor: Sanofi
Acid Sphingomyelinase Deficiency (ASMD)
France
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompleted
NCT02201108Phase 3Updated Feb 6, 2025
Sponsor: Genzyme, a Sanofi Company
Multiple Sclerosis
United States, Belgium, Bulgaria, Canada, China +17 more
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.Completed
NCT05282030Phase 1Updated Feb 6, 2025
Sponsor: Sanofi
Renal Impairment
United States, Germany
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal CancerCompleted
NCT01652196Phase 2Updated Feb 5, 2025
Sponsor: John Hays
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon · Signet Ring Adenocarcinoma of the Rectum
United States
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South AfricaCompleted
NCT04143061Phase 3Updated Feb 3, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunization · Healthy Volunteers
India, South Africa
Resection ObservatoryCompleted
NCT05178745N/AUpdated Jan 30, 2025
Sponsor: Sanofi
Metastatic Colorectal Cancer · Colorectal Neoplasms
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial FibrillationCompleted
NCT05130268Phase 4Updated Jan 28, 2025
Sponsor: American Heart Association
Atrial Fibrillation
United States

Previous page Next page